Pneumococcal Disease trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Pneumococcal Disease. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month2 studies across 2 companies, in the next 180 days.
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six MonthsNCT06622109observationalPercentage of Participants Reporting Adverse Reactions(ADRs) | — | Active, not recruiting | 2026-12-15 | in 117 d | 2026-03-12 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PCVX | Vaxcyte, Inc. | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49NCT07284654Serotype-specific OPA geometric mean titers (GMT) in 50 year olds and above | Phase 3 | Active, not recruiting | Jan 2027 | ≤ 164 d | 2026-05-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Pneumococcal Disease
most recently updated first128 studies match. Showing the first 100 of 128 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | Pfizer | $155.3B | A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy InfantsNCT07573462Percentage of participants reporting local reactions within 7 days after each dose | Phase 3 | Recruiting | Biological: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) | Pneumococcal Disease | 2,400 | 2026-05-04 | 2028-12-30 | in 863 d | 2026-08-10 |
| PFE | Pfizer | $155.3B | A Study to Evaluate 20vPnC in Healthy Chinese InfantsNCT07754539Percentage of participants reporting prespecified local reactions | Phase 3 | Recruiting | Biological: 20vPnC, 13vPnC | Pneumococcal Diseases | 1,250 | 2026-07-25 | 2028-11-30 | in 833 d | 2026-08-10 |
| PFE | Pfizer | $155.3B | A Study to Learn About How a New Pneumococcal Vaccine Works in InfantsNCT06524414Percentage of participants reporting local reactions within 7 days after each dose | Phase 2 | Active, not recruiting | Biological: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15) | Pneumococcal Disease | 605 | 2024-07-25 | 2027-05-01 | in 254 d | 2026-07-09 |
| PFE | Pfizer | $155.3B | A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.NCT07629440Percentage of participants reporting local reactions within 7 days after each dose | Phase 3 | Recruiting | Biological: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) | Pneumococcal Disease | 3,230 | 2026-05-29 | 2029-06-05 | in 1,020 d | 2026-07-09 |
| PFE | Pfizer | $155.3B | Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and AdolescentsNCT07660198Percentage of Participants With Local Reactions Within 7 Days After Vaccination | Phase 3 | Recruiting | Biological: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) | Pneumococcal Disease | 1,200 | 2026-06-15 | 2027-12-02 | in 469 d | 2026-07-09 |
| PCVX | Vaxcyte, Inc. | $8.9B | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgeNCT07365826For each of the 32 serotypes (the 31 serotypes included in VAX-31, and serotype 20B), the ratio (co-administration group to sequential administration group) of opsonophagocytic activity (OPA) geometric mean titers (GMT) in evaluable participants | Phase 3 | Active, not recruiting | Biological: 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo | Pneumococcal Vaccines | 1,390 | 2026-01-12 | Mar 2027 | ≤ 223 d | 2026-06-30 |
| PCVX | Vaxcyte, Inc. | $8.9B | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationNCT07425392Serotype-specific OPA geometric mean titers (GMT) | Phase 3 | Active, not recruiting | Biological: 31-valent pneumococcal conjugate vaccine, PCV20 | Pneumococcal Vaccines | 752 | 2026-02-09 | Mar 2027 | ≤ 223 d | 2026-06-30 |
| PFE | Pfizer | $155.3B | A Study to Learn About How a New Pneumococcal Vaccine Works in AdultsNCT07086677Percentage of participants reporting prespecified local reactions after each dose. | Phase 1 | Active, not recruiting | Biological: PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection | Streptococcus Pneumoniae | 380 | 2025-07-22 | 2027-10-21 | in 427 d | 2026-06-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in AdultsNCT06182124Percentage of participants reporting prespecified local reactions within 7 days after vaccination | Phase 1/2 | Completed | Biological: Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC), Licensed pneumococcal comparator vaccine, Multivalent Pneumococcal Vaccine - Formulation 3, Multivalent Pneumococcal Vaccine - Formulation 4 | Pneumococcal Disease | 1,363 | 2023-12-20 | 2026-05-12actual | — | 2026-06-10 |
| PFE | Pfizer | $155.3B | A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In ChinaNCT01692886Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 mcg/mL 1 Month After the Infant Series in Group 1 And Group 2. | Phase 3 | Completed | Biological: 7-valent Pneumococcal Conjugate Vaccine, 13-valent Pnumococcal Conjugate vaccine, 13-valent Pnumococcal Conjugate vaccine, 13-valent Pnumococcal Conjugate vaccine | Pneumococcal Infection | 1,674 | Sep 2012 | Apr 2014actual | — | 2026-06-02 |
| SNY | Sanofi | — | Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of AgeNCT07348692For all participants: Serotype specific Immunoglobulin g (IgG) Geometric Mean Concentration (GMC) | Phase 3 | Recruiting | Biological: PCV21 vaccine, 20vPCV licensed vaccine | Pneumococcal Immunization, Healthy Volunteers | 2,195 | 2026-01-20 | 2027-06-07 | in 291 d | 2026-05-22 |
| PCVX | Vaxcyte, Inc. | $8.9B | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy InfantsNCT06720038Percentage of subjects with any solicited local injection site adverse events (AE) within 7 days after each vaccination | Phase 2 | Active, not recruiting | Biological: 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31 | Pneumococcal Vaccines | 900 | 2024-11-25 | Dec 2027 | ≤ 498 d | 2026-05-15 |
| PCVX | Vaxcyte, Inc. | $8.9B | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49NCT07284654Serotype-specific OPA geometric mean titers (GMT) in 50 year olds and above | Phase 3 | Active, not recruiting | Biological: 31 valent pneumococcal conjugate vaccine, PCV20, PCV21 | Pneumococcal Vaccines | 4,049 | 2025-12-01 | Jan 2027 | ≤ 164 d | 2026-05-15 |
| SNY | Sanofi | — | Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06824194Presence of any immediate adverse events (AEs) | Phase 3 | Active, not recruiting | Biological: PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix | Pneumococcal Immunization | 2,360 | 2025-02-18 | 2027-10-22 | in 428 d | 2026-04-13 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six MonthsNCT06622109observationalPercentage of Participants Reporting Adverse Reactions(ADRs) | — | Active, not recruiting | Biological: 20-valent Pneumococcal Conjugate Vaccine | Pneumococcal Disease | 1,100 | 2024-11-25 | 2026-12-15 | in 117 d | 2026-03-12 |
| PFE | Pfizer | $155.3B | A Study to Learn More About Prevenar 20 Once it is Out in the Korean MarketNCT06760208observationalFrequency of solicited systemic reactions | — | Recruiting | Biological: Pneumococcal 20-valent conjugate vaccine | Pneumococcal Immunization, Safety | 660 | 2025-11-13 | 2027-03-01 | in 193 d | 2026-03-12 |
| PFE | Pfizer | $155.3B | A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and InfantNCT07023081Percentage of participants reporting prespecified local reactions within 7 days following each study intervention | Phase 1 | Active, not recruiting | Biological: 20vPnC, 13vPnC | Pneumococcal Disease | 200 | 2025-06-15 | 2027-05-14 | in 267 d | 2026-03-12 |
| PFE | Pfizer | $155.3B | A Study to Learn About How a New Pneumococcal Vaccine Works in ChildrenNCT06531538Percentage of participants reporting prespecified local reactions within 7 days after each dose | Phase 2 | Completed | Biological: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) | Pneumococcal Disease | 225 | 2024-07-30 | 2026-02-09actual | — | 2026-03-11 |
| SNY | Sanofi | — | Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06975878Seroresponse rate for PCV21 and 15vPCV serotypes | Phase 3 | Active, not recruiting | Biological: PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccine, M-M-RvaxPro vaccine, Varivax vaccine | Pneumococcal Immunization, Healthy Volunteers | 1,092 | 2025-05-22 | 2027-08-25 | in 370 d | 2026-03-02 |
| PFE | Pfizer | $155.3B | A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese AdultsNCT07019909Percentage of participants reporting prompted local reactions within 7 days following investigational product administration | Phase 1 | Completed | Biological: 20vPnC, 13vPnC | Pneumococcal Disease | 400 | 2025-07-06 | 2026-01-28actual | — | 2026-02-25 |
| SNY | Sanofi | — | Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06824181Presence of any immediate adverse events (AEs) | Phase 3 | Active, not recruiting | Biological: PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix | Pneumococcal Immunization | 580 | 2025-02-27 | 2027-09-10 | in 386 d | 2026-02-13 |
| PFE | Pfizer | $155.3B | A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and TaiwanNCT05512819Percentage of participants in India and Taiwan with local reactions (redness, swelling, and pain at the injection site), separately by country | Phase 3 | Completed | Biological: 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine | Pneumococcal Disease | 541 | 2022-09-16 | 2025-09-20actual | — | 2025-12-15 |
| PCVX | Vaxcyte, Inc. | $8.9B | Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy InfantsNCT05844423Percentage of participants with any solicited local injection site Adverse Events (AE) within 7 days after each vaccination | Phase 2 | Completed | Biological: 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24 | Pneumococcal Vaccines | 802 | 2023-03-29 | 2025-08-25actual | — | 2025-09-11 |
| SNY | Sanofi | — | Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.NCT04583618results2024-08-27Geometric Mean Titers (GMTs) of Pneumococcal Serotypes Using Serotype-Specific MOPA | Phase 2 | Completed | Biological: Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb, Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI, Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII, Pneumococcal 13 - valent conjugate vaccine-Prevnar 13, Pneumococcal Vaccine Polyvalent-Pneumovax 23 | Pneumococcal Immunization | 750 | 2020-10-08 | 2021-08-09actual | — | 2025-09-08 |
| PCVX | Vaxcyte, Inc. | $8.9B | Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in AdultsNCT06151288results2025-07-28Percentage of Subjects Reporting Solicited Local Reactions Within 7 Days After Vaccination (Redness, Swelling, and Pain at Injection Site) in Each Age Group | Phase 1/2 | Completed | Biological: 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine | Pneumococcal Vaccines | 1,015 | 2023-11-08 | 2024-07-17actual | — | 2025-07-28 |
| PFE | Pfizer | $155.3B | A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young ChildrenNCT03574389results2024-04-26The Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of the Pneumococcal Serotypes Measured in Cohorts 2, 3 and 4 Compared to IgG GMCs Measured in Cohort 1 | Phase 3 | Completed | Biological: 13vPnC, Hib | Pneumococcal Infections, Pneumococcal Conjugate Vaccine | 936 | 2018-06-23 | 2021-08-23actual | — | 2024-11-05 |
| PFE | Pfizer | $155.3B | 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and TaiwanNCT04875533results2023-11-28Percentage of Participants With Prompted Local Reactions Within 10 Days After Vaccination 1 (20vPnC or 13vPnC) | Phase 3 | Completed | Biological: 20vPnC, 13vPnC, PPSV23 · Other: Saline | Pneumococcal Disease | 1,425 | 2021-06-14 | 2022-05-13actual | — | 2024-11-05 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.NCT05875727results2024-10-24Percentage of Participants With Local Reactions Within 7 Days After Vaccination | Phase 3 | Completed | Biological: 20-valent pneumococcal conjugate vaccine | Pneumococcal Disease | 405 | 2023-08-16 | 2023-10-02actual | — | 2024-10-24 |
| PCVX | Vaxcyte, Inc. | $8.9B | Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older AdultsNCT05297578results2024-04-16Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination | Phase 2 | Completed | Biological: 24-Valent Pneumococcal Conjugate Vaccine, Pneumococcal 20-valent Conjugate Vaccine | Pneumococcal Vaccines | 207 | 2022-06-15 | 2023-02-15actual | — | 2024-10-09 |
| PFE | Pfizer | $155.3B | Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13NCT05408429results2024-09-19Percentage of Participants With Local Reactions Within 7 Days After Last Vaccination | Phase 3 | Completed | Biological: 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine | Pneumococcal Disease | 356 | 2022-06-24 | 2023-06-01actual | — | 2024-09-19 |
| PFE | Pfizer | $155.3B | Immunization To Prevent Acute COPD ExacerbationsNCT03276754results2024-08-19observationalChange in Adjusted Rate of Moderate/Severe COPD Exacerbations at Month 24 in PCV 13 Population | — | Terminatedsponsor's stated reason: The study was terminated prematurely due to the inability to recruit the planned number of subjects and the interim analysis indicated that the number of included patients did not allow draw any valid conclusion about the main objective of the study | — | Pneumococcal Infections, COPD | 530 | 2017-11-30 | 2022-06-16actual | — | 2024-08-19 |
| PFE | Pfizer | $155.3B | A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to AdultsNCT05831124Percentage of participants reporting local reactions within 7 days after vaccination | Phase 1 | Completed | Other: Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B · Biological: Low dose of multivalent pneumococcal conjugate vaccine control, Standard dose multivalent pneumococcal conjugate vaccine control | Pneumococcal Disease | 90 | 2023-04-19 | 2024-06-26actual | — | 2024-07-29 |
| PFE | Pfizer | $155.3B | A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in IndiaNCT05329259results2024-04-26Percentage of Participants With Prompted Local Reactions Within 7 Days After Vaccination | Phase 4 | Completed | Biological: 13-valent pneumococcal conjugate vaccine | Pneumococcal Disease | 200 | 2022-10-06 | 2022-11-30actual | — | 2024-04-26 |
| PCVX | Vaxcyte, Inc. | $8.9B | Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in AdultsNCT05266456results2024-04-18Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group | Phase 1/2 | Completed | Biological: 24 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine | Pneumococcal Vaccines | 835 | 2022-02-22 | 2023-01-10actual | — | 2024-04-18 |
| PFE | Pfizer | $155.3B | Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of AgeNCT05489328results2024-04-18Percentage of Participants With Local Reactions Within 7 Days After Administration of Study Intervention | Phase 1 | Completed | Other: Candidate-1, Candidate-2, Candidate-3, Candidate-4, Candidate-5, Candidate-6, Candidate Control · Biological: 13vPnC, PCV15 | Pneumococcal Disease | 394 | 2022-08-15 | 2022-10-07actual | — | 2024-04-18 |
| PFE | Pfizer | $155.3B | Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of AgeNCT04642079results2023-04-26Percentage of Participants Reporting Prompted Local Reactions Within 7 Days After Vaccination | Phase 3 | Completed | Biological: 20vPnC | Pneumococcal Disease | 839 | 2020-12-04 | 2022-04-06actual | — | 2024-01-22 |
| PFE | Pfizer | $155.3B | 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy InfantsNCT04546425results2023-05-15Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study Population | Phase 3 | Completed | Biological: 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine | Pneumococcal Disease | 1,258 | 2020-09-09 | 2022-04-22actual | — | 2024-01-08 |
| PFE | Pfizer | $155.3B | 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy InfantsNCT04382326results2023-12-06Percentage of Participants With Local Reactions Within 7 Days After Dose 1 | Phase 3 | Completed | Biological: 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine | Pneumococcal Disease | 1,997 | 2020-05-20 | 2022-09-02actual | — | 2023-12-06 |
| PFE | Pfizer | $155.3B | 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy InfantsNCT04379713results2023-06-13Percentage of Participants With Local Reactions Within 7 Days After Dose 1 | Phase 3 | Completed | Biological: 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine | Pneumococcal Disease | 1,511 | 2020-05-21 | 2022-08-31actual | — | 2023-06-13 |
| PFE | Pfizer | $155.3B | 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese InfantsNCT04530838results2023-04-21Percentage of Participants With Local Reactions (LR) Within 7 Days After Dose 1 | Phase 3 | Completed | Biological: 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine | Pneumococcal Disease | 668 | 2020-09-16 | 2022-04-02actual | — | 2023-04-21 |
| PFE | Pfizer | $155.3B | Serotype Distribution of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in TurkeyNCT01810861observationalIdentification of S. pneumoniae serotype distribution | — | Completed | Other: There is no intervention in this study | Pneumococcal Diseases | 922 | 2013-01-04 | 2019-07-31actual | — | 2023-04-06 |
| PFE | Pfizer | $155.3B | Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2NCT04887948results2022-12-14Percentage of Participants With Local Reactions at Each Injection Site Within 10 Days After Vaccination | Phase 3 | Completed | Biological: 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2 · Other: Saline | Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection | 570 | 2021-05-20 | 2021-12-08actual | — | 2022-12-14 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in TaiwanNCT00688870results2011-05-12Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (mcg)/mL, 1 Month After the Infant Series. | Phase 3 | Completed | Biological: 13-valent pneumococcal conjugate vaccine (13vPnC), 7-valent pneumococcal conjugate vaccine (7vPnC) | Vaccines, Pneumococcal Conjugate Vaccine | 168 | 2008-06-05 | 2010-01-13actual | — | 2022-10-07 |
| PFE | Pfizer | $155.3B | Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of AgeNCT04526574results2022-07-08Percentage of Participants With Local Reactions Within 10 Days After Vaccination With 20vPnC | Phase 3 | Completed | Biological: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC), Influenza vaccine · Other: Saline | Pneumococcal Disease | 1,796 | 2020-09-01 | 2021-06-29actual | — | 2022-07-08 |
| PFE | Pfizer | $155.3B | Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve AdultsNCT03760146results2020-12-29Percentage of Participants With Local Reactions Within 10 Days After Vaccination in All Cohorts | Phase 3 | Completed | Biological: 20vPnC, 13vPnC, PPSV23 · Other: Saline | Pneumococcal Disease | 3,902 | 2018-12-12 | 2019-12-16actual | — | 2021-12-02 |
| PFE | Pfizer | $155.3B | Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy InfantsNCT03550313results2021-11-30Percentage of Participants With Local Reactions Within 7 Days After Dose 1 | Phase 2 | Terminatedsponsor's stated reason: Study vaccinations and blood draws were halted due to adequacy of a smaller dataset and study feasibility issues. It was not based on any safety concerns. | Biological: Multivalent, Prevnar 13 | Pneumococcal Infections | 565 | 2018-06-01 | 2020-11-05actual | — | 2021-11-30 |
| PFE | Pfizer | $155.3B | Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in AdultsNCT00427895results2012-09-05Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1 | Phase 3 | Completed | Biological: 13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS), 13-valent pneumococcal conjugate vaccine (13vPnC), 13-valent pneumococcal conjugate vaccine (13vPnC), 13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS), 13-valent pneumococcal conjugate vaccine (13vPnC) | Pneumococcal Infections | 2,141 | 2007-02-27 | 2011-08-01actual | — | 2021-11-15 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Immune Response In Children Revaccinated With Pneumococcal Conjugate VaccineNCT00853749results2011-01-05Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per Milliliter (mcg/mL) Measured 1 Month After Vaccination | Phase 3 | Completed | Biological: 13-valent pneumococcal conjugate vaccine (13vPnC) · Procedure: Blood draw | Invasive Pneumococcal Disease | 89 | 2009-05-05 | 2009-12-16actual | — | 2021-11-11 |
| PFE | Pfizer | $155.3B | Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy InfantsNCT03512288results2021-03-02Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 | Phase 2 | Completed | Biological: Multivalent, 13vPnC | Pneumococcal Infections | 460 | 2018-04-16 | 2020-02-11actual | — | 2021-03-02 |
| PFE | Pfizer | $155.3B | Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal VaccinationNCT03835975results2021-02-21Percentage of Participants With Local Reactions Within 10 Days After Vaccination | Phase 3 | Completed | Biological: 13vPnC, PPSV23, 20vPnC | Pneumococcal Disease | 875 | 2019-02-12 | 2020-02-12actual | — | 2021-02-21 |
| PFE | Pfizer | $155.3B | Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve AdultsNCT03828617results2020-11-04Percentage of Participants With Local Reactions Within 10 Days After Vaccination | Phase 3 | Completed | Biological: 20vPnC, 20vPnC, 20vPnC, 13vPnC | Pneumococcal Disease | 1,710 | 2019-02-14 | 2019-10-09actual | — | 2020-11-23 |
| PFE | Pfizer | $155.3B | A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of AgeNCT03313050results2020-06-04Stage 1: Percentage of Participants With Local Reactions Within 14 Days After Vaccination | Phase 2 | Completed | Biological: Multivalent, Tdap, polysaccharide | Pneumococcal Infections | 511 | 2017-10-12 | 2019-05-24actual | — | 2020-06-04 |
| PFE | Pfizer | $155.3B | A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.NCT03571607results2019-12-10Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years | Phase 3 | Completed | Biological: 13-valent pneumococcal conjugate vaccine | Pneumococcal Infections | 206 | 2018-07-12 | 2018-11-16actual | — | 2020-02-18 |
| PFE | Pfizer | $155.3B | Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of AgeNCT03313037results2019-12-26Percentage of Participants With Local Reactions Within 10 Days After Vaccination 1 | Phase 2 | Completed | Biological: Multivalent, Prevnar 13, PPSV23 · Other: Saline | Pneumococcal Infections | 444 | 2017-10-10 | 2018-12-10actual | — | 2019-12-26 |
| 051910.KS | LG Chem | $13.7B | A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy InfantsNCT03467984Proportion of subjects achieving pneumococcal serotype-specific IgG >= 0.35 ug/ml | Phase 2 | Completed | Biological: LBVE, Prevnar13 | Pneumococcal Infection | 230 | 2018-05-25 | 2018-10-05actual | — | 2019-08-22 |
| PFE | Pfizer | $155.3B | Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of AgeNCT03642847Subjects reporting prompted local reactions within 14 days after vaccination (redness, swelling, and pain at the injection site). | Phase 1 | Completed | Biological: Prevnar 13, multivalent pneumococcal conjugate formulation 1, multivalent pneumococcal conjugate formulation 2 | Pneumococcal Infections | 104 | 2018-08-29 | 2019-03-29actual | — | 2019-06-12 |
| PFE | Pfizer | $155.3B | Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant RecipientsNCT00980655results2014-04-21Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in All Participants | Phase 3 | Completed | Biological: 13vPnC, 23vPS | Vaccines, Pneumococcal Conjugate Vaccine | 251 | 2010-01-18 | 2013-05-16actual | — | 2018-12-20 |
| PFE | Pfizer | $155.3B | A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and ToddlersNCT01298544results2012-03-16Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody, 36 Months After the Toddler Dose | Phase 4 | Completed | Procedure: Blood draw | Pneumococcal Disease | 335 | Nov 2010 | Mar 2011actual | — | 2018-12-19 |
| PFE | Pfizer | $155.3B | Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal DiseaseNCT01128439observationalIncidence of IPD in the NCKP healthcare system in children 6 weeks through 5 years of age (prior to the sixth birthday) during each of the 5 years following introduction of Prevnar 13. | — | Completed | Other: No intervention | Invasive Pneumococcal Disease | 1 | Jul 2010 | Apr 2015actual | — | 2018-12-04 |
| PFE | Pfizer | $155.3B | Serotype Distribution of Chest X-ray Confirmed Pneumococcal Community Acquired Pneumonia in the Adult Population in Greece, Over 1 Year.NCT01564771observationalThe frequency of serotypes 4,6B,9V,14,18C,19F,23F,1,3,5,6A,7F and 19A from chest X-ray confirmed pCAP patients (post amendment2 with positive Binax NOW® only) who presented in the emergency departments of 15 hospitals in Greece during 1 | — | Completed | Other: Non Intervention | Pneumococcal Disease | 293 | Jan 2011 | Apr 2013actual | — | 2018-12-03 |
| PFE | Pfizer | $155.3B | A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 YearsNCT02955160Percentage of subjects reproting prompted local reactions within 14 days after vaccination (redness, swelling. limitation of arm movement, and pain at injection site). | Phase 1 | Completed | Biological: Multivalent, Tdap | Pneumococcal Infections | 66 | 2016-11-03 | 2017-08-01actual | — | 2018-09-11 |
| PFE | Pfizer | $155.3B | A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese SubjectsNCT01531322Number of participants reporting Adverse Events | Phase 1 | Completed | Biological: 13-valent Pneumococcal Conjugate Vaccine, 13-valent Pneumococcal Conjugate Vaccine, 13-valent Pneumococcal Conjugate Vaccine | Pneumococcal Infection | 72 | Oct 2011 | Jan 2012actual | — | 2018-09-07 |
| 051910.KS | LG Chem | $13.7B | A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy AdultsNCT03549208Solicited adverse events | Phase 1 | Unknown status | Biological: LBVE01, LBVE02, Prevnar13 | Pneumococcal Infection | 60 | 2018-07-01 | 2019-04-01 | — | 2018-06-13 |
| PFE | Pfizer | $155.3B | Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.NCT01193335results2015-02-04Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After Infant Series | Phase 4 | Completed | Biological: 13-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine | 13-valent Pneumococcal Vaccine, Premature Birth, Immunization, Safety | 200 | Oct 2010 | Jan 2014actual | — | 2017-05-11 |
| PFE | Pfizer | $155.3B | Post Market Surveillance to Observe Safety of Prevenar13™ in AdultsNCT01834222results2017-04-18observationalNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | — | Completed | Biological: Non-intervention | Pneumococcal Disease | 659 | Dec 2013 | Mar 2016actual | — | 2017-04-18 |
| PFE | Pfizer | $155.3B | Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among FilipinosNCT01396434results2017-01-30observationalNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | — | Completed | Biological: Prevenar 13 | Pneumococcal Disease | 3,006 | Dec 2011 | May 2014actual | — | 2017-01-30 |
| PFE | Pfizer | $155.3B | Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)NCT01521897results2016-01-20observationalNumber of Participants With Adverse Reactions | — | Completed | Biological: 7-valent vaccine injection | Pneumococcal Vaccine, Streptococcus Pneumoniae | 1,143 | Sep 2010 | Jan 2013actual | — | 2016-01-20 |
| PFE | Pfizer | $155.3B | 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.NCT01964716results2015-03-13Percentage of Participants Achieving a Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal To (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series for Each Vaccine Group | Phase 3 | Completed | Biological: 13-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine | Pneumococcal Vaccines | 500 | Jan 2014 | Sep 2014actual | — | 2015-03-13 |
| PFE | Pfizer | $155.3B | Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal VaccineNCT00962780results2014-11-17Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All Participants | Phase 3 | Completed | Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) · Procedure: Blood draw, Blood draw | HIV Infections, Pneumococcal Infections | 303 | Mar 2010 | Apr 2013actual | — | 2014-11-17 |
| PFE | Pfizer | $155.3B | Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in AdultsNCT00744263results2014-10-06Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP) | Phase 4 | Completed | Biological: VACCINE: placebo, VACCINE: 13-valent pneumococcal conjugate vaccine | Pneumonia, Pneumococcal, Pneumococcal Infections, 13-valent Pneumococcal Vaccine | 84,496 | Sep 2008 | Oct 2013actual | — | 2014-10-06 |
| PFE | Pfizer | $155.3B | Postlicensure Observational Safety Study of 13vPnC Administered to Infants and ToddlersNCT01128426results2014-07-14observationalRelative Risk of Medically Attended Events Between 30-day Risk Window and 30-day Self-control Window: Pre-Dose 1 Inpatient | — | Completed | Other: No Intervention | Pneumococcal Disease | 53,902 | Jun 2010 | Jun 2013actual | — | 2014-07-14 |
| PFE | Pfizer | $155.3B | Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell DiseaseNCT00918580results2014-04-21Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 1 Month After 13vPnC Dose 1 to 1 Month After 13vPnC Dose 2 | Phase 3 | Completed | Biological: 13-valent Pneumoccocal Conjugate Vaccine | Pneumococcal Conjugate Vaccine | 158 | Nov 2009 | Mar 2013actual | — | 2014-04-21 |
| PFE | Pfizer | $155.3B | Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®NCT01392378results2014-02-26Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series | Phase 4 | Completed | Biological: 13-valent pneumococcal conjugate vaccine, INFANRIX hexa, 13-valent pneumococcal conjugate vaccine, INFANRIX hexa, 13-valent pneumococcal conjugate vaccine, INFANRIX hexa, 13-valent pneumococcal conjugate vaccine, INFANRIX hexa, 13-valent pneumococcal conjugate vaccine, INFANRIX hexa · Drug: Paracetamol, Ibuprofen, Paracetamol, Ibuprofen | Pneumococcal Vaccines | 908 | Aug 2011 | Jan 2013actual | — | 2014-02-26 |
| PFE | Pfizer | $155.3B | Nasopharyngeal Streptococcus Pneumoniae CarriageNCT00471822results2013-11-20observationalPercentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx | — | Completed | — | Streptococcus Pneumoniae Infections | 9,707 | Jul 2005 | Dec 2010actual | — | 2013-11-20 |
| PFE | Pfizer | $155.3B | A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal BacteriaNCT01193582results2013-11-20Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar | Phase 4 | Completed | Biological: Prevenar, Prevenar, Prevenar, Prevenar | Pneumococcal Infections | 505 | Sep 2010 | Sep 2012actual | — | 2013-11-20 |
| PFE | Pfizer | $155.3B | A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and OlderNCT01646398results2013-09-20Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 12 Common Serotypes 1 Month After Vaccination | Phase 3 | Completed | Biological: 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine | Pneumococcal Vaccines, Pneumococcal Conjugate Vaccine | 764 | Jun 2012 | Oct 2012actual | — | 2013-09-20 |
| PFE | Pfizer | $155.3B | Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPSNCT00963235results2013-06-10Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC | Phase 3 | Completed | Biological: 13-valent pneumococcal conjugate vaccine · Procedure: Blood draw | HIV Infections, Pneumococcal Infections | 331 | Nov 2009 | May 2012actual | — | 2013-06-10 |
| PFE | Pfizer | $155.3B | Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal ColonizationNCT00508742results2012-07-13Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age | Phase 3 | Completed | Biological: 13-valent Pneumococcal Conjugate Vaccine, 7 valent pneumococcal conjugate vaccine | Pneumococcal Infections | 1,866 | Dec 2007 | Aug 2011actual | — | 2013-05-10 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy InfantsNCT00474539results2013-03-05Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series | Phase 3 | Completed | Biological: 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine | Vaccines, Pneumococcal | 449 | Jul 2007 | Mar 2009actual | — | 2013-03-05 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in InfantsNCT00366899results2013-02-22Percentage of Participants Reporting Pre-Specified Local Reactions | Phase 3 | Completed | Biological: 13-valent pneumococcal conjugate vaccine, 7 valent pneumococcal conjugate vaccine | Vaccines, Pneumococcal | 605 | Oct 2006 | Jul 2008actual | — | 2013-02-22 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix HexaNCT00294294Rectal temperature >= 38°C within days 1-4 post vaccination after any of the doses 1-4 | Phase 4 | Completed | Biological: Prevenar, Infanrix hexa | Vaccines, Pneumococcal, Infant, Fever, Chemically Induced, Drug Therapy, Combination | 300 | May 2005 | Dec 2006actual | — | 2013-02-21 |
| PFE | Pfizer | $155.3B | Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate VaccineNCT00373958results2013-02-21Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series | Phase 3 | Completed | Biological: 13 valent pneumococcal conjugate vaccine, 7vPnc pneumococcal conjugate vaccine | Vaccines, Pneumococcal | 666 | Sep 2006 | Jun 2008actual | — | 2013-02-21 |
| PFE | Pfizer | $155.3B | 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in MexicoNCT01432262results2013-01-08Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination | Phase 3 | Completed | Biological: vaccine-13vPnC, vaccine-13vPnC | Pneumococcal Infections | 324 | Jul 2011 | Dec 2011actual | — | 2013-01-25 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in InfantsNCT00384059results2012-08-15Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series. | Phase 3 | Completed | Biological: 13-valent Pneumococcal Conjugate Vaccine, 7vPnC, Pediacel, NeisVac-C, Menitorix | Vaccines, Pneumococcal | 286 | Oct 2006 | Oct 2008actual | — | 2013-01-24 |
| PFE | Pfizer | $155.3B | Child Pneumococcal Serotype Epidemiology In GreeceNCT01111214observationalThe serotype distribution of invasive S. pneumoniae isolates of hospitalized children up to 14 years of age after the introduction of the 7-valent conjugate pneumococcal vaccine | — | Completed | Other: no intervention | Pneumococcal Disease | 457 | Nov 2011 | Nov 2012actual | — | 2013-01-10 |
| PFE | Pfizer | $155.3B | Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.NCT00227188observational | — | Completed | Drug: Pneumococcal 7-valent conjugate vaccine Prevnar | Invasive Pneumococcal Disease | 408 | May 2003 | Dec 2005actual | — | 2012-11-29 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy InfantsNCT00444457results2010-07-14Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series | Phase 3 | Completed | Biological: 13-valent Pneumococcal Conjugate Vaccine, 7vPnC | Vaccines, Pneumococcal | 1,712 | May 2007 | Jun 2009actual | — | 2012-10-15 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.NCT00368966results2012-08-16Percentage of Participants Achieving Predefined Meningococcal C Serum Bactericidal Assay (SBA) Titer of ≥ 1:8, and a Predefined Antibody Level for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series | Phase 3 | Completed | Biological: 13-valent Pneumococcal Conjugate Vaccine, 7-valent Pneumococcal Conjugate Vaccine | Vaccines, Pneumococcal | 619 | Oct 2006 | Jul 2008actual | — | 2012-08-16 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating Pneumococcal Vaccine in Healthy InfantsNCT00205803results2012-08-15Percentage of Participants Reporting Pre-Specified Local Reactions | Phase 1/2 | Completed | Biological: 13-Valent Pneumococcal Conjugate Vaccine (13vPnC), 7-Valent Pneumococcal Conjugate Vaccine (7vPnC) | Healthy Subjects, Pneumococcal Infections | 249 | Sep 2004 | — | — | 2012-08-15 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in InfantsNCT00366548results2012-08-15Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC+P80 Group Relative to 13vPnC-80 Group After the Infant Series | Phase 3 | Completed | Biological: 13 valent pneumococcal conjugate vaccine with Polysorbate 80, 13 valent pneumococcal conjugate vaccine without Polysorbate 80 | Vaccines, Pneumococcal | 500 | Nov 2006 | Jun 2008actual | — | 2012-08-15 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in InfantsNCT00366678results2012-08-15Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin (PT) and Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group | Phase 3 | Completed | Biological: 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine · Drug: Pentavac | Vaccines, Pneumococcal | 613 | Oct 2006 | Nov 2008actual | — | 2012-08-15 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and ChildrenNCT00452452results2012-08-15Percentage of Participants Achieving Antibody Level ≥0.35μg/mL After Vaccination | Phase 3 | Completed | Biological: 13-valent Pneumococcal Conjugate Vaccine | Pneumococcal Infections | 355 | Jul 2007 | Mar 2008actual | — | 2012-08-15 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in InfantsNCT00464945results2012-08-15Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series | Phase 3 | Completed | Biological: 13-valent Pneumococcal Conjugate Vaccine | Pneumococcal Vaccines | 269 | Jun 2007 | Sep 2008actual | — | 2012-08-15 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.NCT00366340results2012-08-08Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series | Phase 3 | Completed | Biological: 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine | Vaccines, Pneumococcal | 604 | Oct 2006 | Aug 2008actual | — | 2012-08-08 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese InfantsNCT00574795results2012-08-08Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series | Phase 3 | Completed | Biological: 13vPnC | Vaccines, Pneumococcal Conjugate Vaccine | 193 | Sep 2007 | Aug 2008actual | — | 2012-08-08 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children of 12-18 Months in 6 Cities, ChinaNCT00952367results2012-04-23observationalPercentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae | — | Completed | Other: Nasopharyngeal swab | Streptococcus Pneumoniae Infections | 3,641 | Apr 2009 | Mar 2010actual | — | 2012-04-23 |
| PFE | Pfizer | $155.3B | Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet JapanNCT00757575observational1.Describe the distribution of causal pathogen of meningitis and bacteremia 2.Estimate the hospital admission rate of pneumonia patients 3.Estimate the incidence rate of IPD 4.Describe the serotype distribution of S. pneumoniae | — | Completed | — | Pneumococcal Disease | 28,511 | Feb 2008 | Oct 2010actual | — | 2012-03-27 |
| PFE | Pfizer | $155.3B | Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.NCT00743652results2012-02-10Percentage of Participants Achieving Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 Micrograms Per Milliliter (Mcg/mL) 1 Month After the Infant Series | Phase 3 | Completed | Biological: 13-valent Pneumococcal Conjugate Vaccine, 13-valent Pneumococcal Conjugate Vaccine, 13-valent Pneumococcal Conjugate Vaccine, 13-valent Pneumococcal Conjugate Vaccine, 13-valent Pneumococcal Conjugate Vaccine | Pneumococcal Disease, 13-valent Pneumococcal Vaccine | 373 | Jan 2009 | Sep 2010actual | — | 2012-03-15 |
| PFE | Pfizer | $155.3B | Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired PneumoniaNCT01086397observationalProportion of subjects who have vaccine-type (VT), ie, PCV13, S. pneumoniae. | — | Completed | Procedure: Urine sample collection | Pneumonia, Pneumococcal, Vaccines, Pneumococcal | 782 | Feb 2010 | Sep 2011actual | — | 2012-03-15 |
| PFE | Pfizer | $155.3B | Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in AdultsNCT00492557results2012-02-17TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI) | Phase 3 | Completed | Biological: 13-valent pneumococcal conjugate vaccine, 13vPnC + TIV | Pneumococcal Infections | 1,185 | Sep 2007 | Feb 2008actual | — | 2012-02-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Pneumococcal Disease is matched — 16 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Pneumococcal Disease
- Pneumococcal Infections
- Pneumococcal Vaccines
- Vaccines, Pneumococcal
- Vaccines, Pneumococcal Conjugate Vaccine
- Pneumococcal Immunization
- Pneumococcal Conjugate Vaccine
- 13-valent Pneumococcal Vaccine
- Pneumococcal Infection
- Invasive Pneumococcal Disease
- Pneumonia, Pneumococcal
- Streptococcus Pneumoniae Infections
- Pneumococcal Diseases
- Pneumococcal Pneumonia
- Pneumococcal Vaccine
- Streptococcus Pneumoniae
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Pneumococcal Disease” (a text search, wider than this page)